UNSPSC 51384517: Suprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H12O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 988GU2F9PE, chemically known as r-25,061 but generally known as suprofen, which bears US NIH Compound Identifier 5359. European Medicines Agency schedules Suprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10778MIG.

UNSPSC 51384517 Suprofen is a Commodity code that nominally covers a single nonsteroidal anti-inflammatory drug, but recent state and local activity under this code shows little alignment with the specific pharmaceutical named. The three most recent opportunities posted under the code actually solicit for naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch suggests that state and local procurement systems are either tagging these opportunities with an incorrect UNSPSC code or using the code as a catch-all for pharmaceutical acquisition rather than for suprofen specifically. The issuing bodies represent a mix of county government (Seminole County), state health agencies (Texas HHS), and cooperative purchasing organizations serving multiple state and local jurisdictions (MMCAP, which includes Minnesota and Oregon).

Activity is geographically scattered across Florida, Texas, Minnesota, and Oregon with no identifiable concentration. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2026) seeks annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems through competitive bidding with quarterly deliveries to the county's Community Health Building. The Texas HHS Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program — an exploratory phase aimed at informing future formal solicitation strategy rather than committing to specific contract amounts. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluations weighted heavily on price competitiveness (75 percent) and contract effectiveness July 1, 2026. The code shows recent activity but limited relevance to suprofen itself; opportunities pursue broader pharmaceutical sourcing and public health initiatives rather than this specific drug product.